Palifermin
| Clinical data | |
|---|---|
| AHFS/Drugs.com | monograph |
| MedlinePlus | a605017 |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 162394-19-6  |
| ATC code | V03AF08 |
| DrugBank | BTD00042 |
| UNII | QMS40680K6 |
| ChEMBL | CHEMBL1201821  |
| Chemical data | |
| Formula | C721H1142N202O204S9 |
| Mol. mass | 16192.7 g/mol |
 (what is this?) (verify) |
|
Palifermin (trade name Kepivance, marketed by Biovitrum) is a human recombinant keratinocyte growth factor (KGF)[1] produced in Escherichia coli. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract.[2]
Contents |
[edit] Uses
When patients with blood cancers (leukemia and lymphoma) receive high dose chemotherapy and radiation therapy to undergo bone marrow transplantation, they usually get severe oral mucositis.[3] Palifermin binds to epithelial cell-surface receptors and stimulates epithelial cell proliferation, differentiation, and upregulation of cytoprotective mechanisms. It reduces the incidence and duration of severe oral mucitis[4][5] by protecting those cells and stimulating the growth of new epithelial cells to build up the mucosal barrier.
Palifermin is also being studied in the prevention and treatment of oral mucositis and dysphagia (difficulty swallowing) in other types of cancer.[2]
[edit] Costs
Palifermin costs approximately 5,000 Euros per treatment for a 70 kg patient.[6]
[edit] References
- ^ Beaven AW, Shea TC (September 2007). "The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature". Support Cancer Ther 4 (4): 188–97. doi:10.3816/SCT.2007.n.014. PMID 18632516. http://cigjournals.metapress.com/openurl.asp?genre=article&id=doi:10.3816/SCT.2007.n.014.
- ^ a b Kepivance entry in the public domain NCI Dictionary of Cancer Terms
- ^ Blijlevens N, Sonis S (May 2007). "Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis". Ann. Oncol. 18 (5): 817–26. doi:10.1093/annonc/mdl332. PMID 17030544. http://annonc.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17030544.
- ^ Spielberger R, Stiff P, Bensinger W, et al. (December 2004). "Palifermin for oral mucositis after intensive therapy for hematologic cancers". N. Engl. J. Med. 351 (25): 2590–8. doi:10.1056/NEJMoa040125. PMID 15602019. http://content.nejm.org/cgi/pmidlookup?view=short&pmid=15602019&promo=ONFLNS19.
- ^ McDonnell AM, Lenz KL (January 2007). "Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis". Ann Pharmacother 41 (1): 86–94. doi:10.1345/aph.1G473. PMID 17190850. http://www.theannals.com/cgi/pmidlookup?view=long&pmid=17190850.
- ^ NEW DRUGS in TRANSPLANTATION, EBMT Meeting, France, March 2007 C. PAILLET, Pharmacist, Pharm D. C. RENZULLO, Pharmacist, Pharm D. Edouard Herriot Hospital, Lyon, FRANCE
[edit] External links
|
|||||||||||||||||||||||||
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
